ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
Summary
Research efforts will encompass mechanism of action (MOA) studies, efficacy and safety verification, and database construction for new drug candidates targeting the identified molecules through multi-omics analysis. All research activities up to the preclinical stage will be conducted using patient-derived systems, alongside the development of companion diagnostics for patient selection.Yong-Bae Kim, CEO and Principal Investigator of ReCerise Therapeutics, emphasized, "The need for new cancer treatment strategies to overcome resistance to current therapies has been consistently highlighted. We will strive to implement strategies to maximize the efficacy and safety in clinical stages and ensure that they translate into competitive drugs in the global market. "ReCerise Therapeutics, established in 2020, is a pioneering South Korean biotech company dedicated to advancing first-in-class treatments for liver cancer and liver-related diseases. Recently, it was selected for the Baby Unicorn 200 Nurturing Project overseen by a Korean government organization, the Ministry of Small and Medium-sized Enterprises (SMEs) and Startups.